Revisiting Treatment Strategies: Addressing Epithelial-to-Mesenchymal Transition-Induced Resistance in Hepatocellular Carcinoma
BME Frontiers · 2025-01 · 6
DOI: 10.34133/bmef.0144 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BME Frontiers, online erschienen am 24.06.2025. Verfasst von Roghayeh Naserkhaki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Developmental Biology, University of Science and Culture, Tehran 1665658822, Iran. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 228 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
One of the major therapeutic challenges for hepatocellular carcinoma (HCC), the most form of primary liver cancer, is how to overcome drug resistance. Due to the high failure rate of systemic therapy in treating advanced HCC patients and the increasing recurrence rate, HCC is a highly lethal malignancy. Primary and acquired drug resistance are major contributing factors to the patients with advanced HCC who do not respond effectively to long-term systemic therapy. Therefore, it is essential to look into the molecular processes that lead to drug resistance. Different studies have indicated that epithelial-to-mesenchymal transition (EMT) plays a critical part in the emergence of drug resistance. Several signaling pathways regulate this phenomenon. This review primarily concentrates on drug resistance triggered by EMT, especially in the context of HCC. The key signaling pathways that cause drug resistance in HCC, including transforming growth factor-β and epidermal growth factor receptor signaling, liver cancer stem cells, and noncoding RNAs, are highlighted in the present study, along with the most recent molecular targets discovered to prevent drug resistance. These targets could help develop novel and combinatory HCC therapy approaches. Therefore, this review aims to provide both the latest findings on molecular basis and potential solutions for HCC drug resistance.
Autor:innen und Institutionen
- Department of Developmental Biology, University of Science and Culture, Tehran 1665658822, Iran.
- Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran 1665659911, Iran.
- Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
- Department of Basic and Population Based Studies in NCD, Reproductive Epidemiology Research Center, Royan Institute, ACECR, Tehran, Iran.
- Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, Istanbul Okan University, Istanbul 34959, Turkiye.
- Independent Researcher, Isfahan, Iran.
ORCID-Profile: Siavash Iravani, Massoud Vosough
Zitieren
APA
Naserkhaki, R., Shokouhian, B., Tahamtani, Y., Khosravi, A., Iravani, S., Zarrabi, A., & Vosough, M. (2025). Revisiting Treatment Strategies: Addressing Epithelial-to-Mesenchymal Transition-Induced Resistance in Hepatocellular Carcinoma. BME Frontiers, 6. https://doi.org/10.34133/bmef.0144
Vancouver
Naserkhaki R, Shokouhian B, Tahamtani Y, Khosravi A, Iravani S, Zarrabi A, et al. Revisiting Treatment Strategies: Addressing Epithelial-to-Mesenchymal Transition-Induced Resistance in Hepatocellular Carcinoma. BME Frontiers. 2025;6. doi:10.34133/bmef.0144
BibTeX
@article{Naserkhaki2025,
author = {Naserkhaki, Roghayeh and Shokouhian, Bahare and Tahamtani, Yaser and Khosravi, Arezoo and Iravani, Siavash and Zarrabi, Ali and Vosough, Massoud},
title = {Revisiting Treatment Strategies: Addressing Epithelial-to-Mesenchymal Transition-Induced Resistance in Hepatocellular Carcinoma},
journal = {BME Frontiers},
year = {2025},
volume = {6},
doi = {10.34133/bmef.0144}
}
EUVIMED